Pharmacogenomic considerations in the opioid management of pain
Authors:
Open Access
- 1 January 2010
- journal article
- review article
- Published by Springer Nature in Genome Medicine
- Vol. 2 (9) , 66
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- UGT2B7 promoter variant −840G>A contributes to the variability in hepatic clearance of morphine in patients with sickle cell diseaseAmerican Journal of Hematology, 2007
- Human Opioid Receptor A118G Polymorphism Affects Intravenous Patient-controlled Analgesia Morphine Consumption after Total Abdominal HysterectomyAnesthesiology, 2006
- Association of μ‐opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplastyActa Anaesthesiologica Scandinavica, 2006
- The Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patientsPain, 2005
- Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and futureTrends in Pharmacological Sciences, 2004
- Impact of CYP2D6 genotype on postoperative tramadol analgesiaPain, 2003
- The minimally effective concentration of adrenaline in a low‐concentration thoracic epidural analgesic infusion of bupivacaine, fentanyl and adrenaline after major surgery A randomized, double‐blind, dose‐finding study.Acta Anaesthesiologica Scandinavica, 2003
- Morphine and alternative opioids in cancer pain: the EAPC recommendationsBritish Journal of Cancer, 2001
- No pain relief from codeine...?. An introduction to pharmacogenomicsActa Anaesthesiologica Scandinavica, 2001
- Cancer pain relief and palliative care. Report of a WHO Expert Committee.1990